EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosis

Nevin A John, Yingtong Li, Floriana De Angelis, Jonathan Stutters iD, Ferran Prados, Anisha Doshi, Alberto Calvi iD, Thomas Williams iD, Domenico Plantone, Thanh Phan, Claudia A M Gandini Wheeler-Kingshott, Frederik Barkhof und 2 weitere

European Journal of Neurology · 2025

DOI: 10.1111/ene.16586 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Nevin A John und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Atrophy, Gray Matter, Multiple Sclerosis, Chronic Progressive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIHR, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Comorbidities including vascular risk factors can be associated with whole and regional brain atrophy in multiple sclerosis (MS). This has been examined in mixed MS cohorts in prospective or observational studies; however, the association between vascular comorbidities (VCM) in secondary progressive MS (SPMS) and brain atrophy has been less well studied. The aim was to investigate the cross‐sectional and longitudinal association between VCM, comorbidity burden and brain atrophy in SPMS.

Methods

Post hoc analysis of 445 participants from the MS–Secondary Progressive multi‐arm trial (MS‐SMART)−a multi‐arm multicentre phase‐2b randomised placebo‐controlled trial of three agents in SPMS (NCT01910259). VCM (hypertension, hyperlipidaemia) but also asthma, hypothyroidism and osteoporosis were recorded. Regional and whole brain volume (WBV), and percentage brain volume change were calculated using SIENAX and SIENA, respectively. Multiple linear regression was used to investigate the cross‐sectional and longitudinal relationships between VCM, overall comorbidity count and whole brain, grey matter (GM) and white matter (WM) atrophy.

Results

The cohort was predominantly female (67%), mean age 55 with median EDSS 6.0. In total, 13% and 9% had hypertension and hyperlipidaemia, respectively. In cross‐sectional regression models, VCM was associated with decreased cortical GM volume [(hypertension β = −0.30, 95%CI −0.54 to −0.06, p = 0.01) (hyperlipidaemia β = −0.37, 95%CI −0.64 to −0.09, p = 0.008)]; but not WBV. Having ≥2 comorbidities was also associated with decreased cortical GM volume ( β = −0.36, 95%CI −0.61 to −0.10, p = 0.007). No relationship was observed between VCM/comorbidity count and whole brain or GM atrophy rate over 96 weeks.

Conclusions

People with SPMS with VCM or increased overall comorbidity burden showed reduced whole brain and especially cortical grey matter volumes, but no significant impact on subsequent 2‐year atrophy rate was detected.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtrophyGray MatterMultiple Sclerosis, Chronic ProgressiveAdultAgedFemaleHumansMaleMiddle AgedComorbidityCross-Sectional StudiesHypertensionLongitudinal StudiesMagnetic Resonance ImagingRisk FactorsWhite Matter

Stichwörter der Autor:innen

comorbiditiesmultiple sclerosissecondary progressive

Autor:innen und Institutionen

  • Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
  • Department of Neurology, Monash Health, Melbourne, Victoria, Australia.
  • Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Centre for Medical Image Computing (CMIC), University College London, London, UK.
  • e-Health Center, Universitat Oberta de Catalunya, Barcelona, Spain.
  • Laboratory of Advanced Imaging in Neuroimmunological Diseases (imaginEM), Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), Barcelona, Spain.

ORCID-Profile: Jonathan Stutters, Alberto Calvi, Thomas Williams

Förderung

  • NIHR
  • National Institute for Health and Care Research

Zitieren

APA

John, N. A., Li, Y., De Angelis, F., Stutters, J., Prados, F., Doshi, A., Calvi, A., Williams, T., Plantone, D., Phan, T., Gandini Wheeler-Kingshott, C. A. M., Barkhof, F., Chataway, J., & MS‐SMART Investigators (2025). Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.16586

Vancouver

John NA, Li Y, De Angelis F, Stutters J, Prados F, Doshi A, et al. Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosis. European Journal of Neurology. 2025. doi:10.1111/ene.16586

BibTeX
@article{John2025,
  author = {John, Nevin A and Li, Yingtong and De Angelis, Floriana and Stutters, Jonathan and Prados, Ferran and Doshi, Anisha and Calvi, Alberto and Williams, Thomas and Plantone, Domenico and Phan, Thanh and Gandini Wheeler-Kingshott, Claudia A M and Barkhof, Frederik and Chataway, Jeremy and MS‐SMART Investigators, MS‐SMART Investigators},
  title = {Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosis},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.16586}
}
Kostenlos starten →